Complement C3 — Drug Target

All drugs that target Complement C3 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Complement C3 inhibitor · Complement C3 inhibitor (aptamer)

Marketed (1)

• Izervay™ · Hoffmann-La Roche · Complement C3 inhibitor · Ophthalmology
  Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.

Phase 3 pipeline (5)

• APL-2, Pegcetacoplan · Apellis Pharmaceuticals, Inc. · Complement C3 inhibitor · Immunology / Rare Disease
  Pegcetacoplan is a complement C3 inhibitor that blocks the activation and amplification of the complement cascade by targeting C3.
• APL-2 · Apellis Pharmaceuticals, Inc. · Complement C3 inhibitor · Immunology
  APL-2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.
• ALXN1850 · Alexion Pharmaceuticals, Inc. · Complement C3 inhibitor · Nephrology / Immunology
  ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.
• ALXN2060 · Alexion Pharmaceuticals, Inc. · Complement C3 inhibitor · Immunology / Hematology
  ALXN2060 is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage.
• Placebo matching Pegcetacoplan · Swedish Orphan Biovitrum · Complement C3 inhibitor (aptamer) · Immunology / Rare Disease
  This is a placebo control arm matching the active drug pegcetacoplan, which is a complement C3 inhibitor that blocks the alternative complement pathway.